GlaxoSmithKline (GSK) Announces Approval In Canada For Incruse™ Ellipta™ (Umeclidinium) As A Treatment For COPD
4/17/2014 4:37:25 PM
MISSISSAUGA, ON, April 17, 2014 /CNW/ - GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This is the first market authorisation granted for this product anywhere in the world.
Help employers find you! Check out all the jobs and post your resume.
comments powered by